ELI LILLY AND COMPANY Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31)
ELI LILLY AND COMPANY (LLY) had Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) of $162.60 million as of 2013-03-31, per its 10-Q filed 2013-04-26.
Discontinued › Notes › Investments
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGain · last filed 2013-04-26
- 2013-03-31: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $162.60M.
- 2012-12-31: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $140.50M.
- 2012-09-30: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $150.60M.
- 2012-06-30: Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) $136.00M.
| Period end | Available-for-sale Securities, Gross Unrealized Gains (Deprecated 2013-01-31) |
|---|---|
| 2013-03-31 | $162.60M 10-Q · filed 2013-04-26 |
| 2012-12-31 | $140.50M 10-Q · filed 2013-04-26 |
| 2012-09-30 | $150.60M 10-Q · filed 2012-10-26 |
| 2012-06-30 | $136.00M 10-Q · filed 2012-07-27 |
| 2012-03-31 | $124.80M 10-Q · filed 2012-04-30 |
| 2011-12-31 | $103.00M 10-K · filed 2013-02-21 |
| 2011-09-30 | $78.10M 10-Q · filed 2011-10-28 |
| 2011-06-30 | $184.50M 10-Q · filed 2011-07-29 |
| 2011-03-31 | $281.30M 10-Q · filed 2011-04-29 |
| 2010-12-31 | $262.60M 10-K · filed 2012-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |